• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ANGIODYNAMICS, INC. SMART PORT CT; PORT & CATHETER, IMPLANTED, SUBCUTANEOUS, INTRAVASCULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ANGIODYNAMICS, INC. SMART PORT CT; PORT & CATHETER, IMPLANTED, SUBCUTANEOUS, INTRAVASCULAR Back to Search Results
Model Number H787CT66LTPDVI1
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Codes Dyspnea (1816); Fatigue (1849); Drug Resistant Bacterial Infection (4553)
Date of Event 04/07/2025
Type of Reportable Event Death
Event or Problem Description
On or about on (b)(6) 2025, decedent underwent placement of an angiodynamics smartport, with model number: h787ct66ltpdvi1 and lot number: a4524037.The smartport device was compromised of a port body and a polyurethane catheter.The device was implanted by dr.(b)(6), m.D., at (b)(6), for chemotherapy treatment.On or about on (b)(6) 2025, decedent presented to (b)(6) with fatigue and shortness of breath.Blood cultures were drawn and returned positive for mrsa, necessitating removal of the smartport.On or about on (b)(6) 2025, the defective device was removed by dr.(b)(6), m.D., at (b)(6).On or about on (b)(6) 2025, decedent passed away.
 
Additional Manufacturer Narrative
The device is not available to be returned to the manufacturer for evaluation.An investigation into the root cause for the event is currently in progress.The results of the investigation will be sent via a follow up medwatch.Reference: (b)(4).
 
Additional Manufacturer Narrative
The customer's reported complaint description of patient infection cannot be confirmed given the patient centric nature of this serious adverse event (sae).No port device was returned for evaluation since there was no report of port device malfunction, damage or performance issue during in situ use/treatment.A device history record (dhr) review of the indicated packaging lot revealed no quality related issues or manufacturing deficiencies at the time of manufacture.Sterilization load release records were reviewed for the packaging lot in question; no issues were observed.The port was implanted into the patient 12 days prior to the patient's infection.There was no report of port device malfunction or performance issue during use.Potential root cause for infection is the port implant procedure and/or port access.Device directions for use (dfu) cautions that each access of the port should be performed using aseptic technique, following the institutions universal precautions.There is no indication from the reported complaint and dhr/sterilization record review that the manufacturing/packaging/sterilization of the port device could have contributed to the patient's infection.Infection is cautioned in the device dfu as a potential complication of port system use.Labeling review: the directions for use (dfu) that is provided with the port device contains the following statements: warnings: · the device is to be implanted, used, maintained, and removed in strict accordance with institutional and or centers for disease control (cdc) guidelines or policies.· reuse of single-use devices creates a potential risk of patient or user infections.Contamination of the device may lead to injury, illness or death of the patient.· do not use syringes smaller than 10 ml syringe when accessing the port as system damage can occur.Flushing occluded catheters with small syringes can create excessive pressures within the port system.Precautions · carefully read and follow all instructions prior to use.· strict aseptic technique is of paramount importance when implanting any device.· for peripheral placement, irritation to the vein, resulting in postoperative thrombophlebitis, has been associated with guidewire and introducer insertion.· when using percutaneous introducers: to avoid blood vessel damage, do not allow the percutaneous introducer sheath to remain indwelling in the blood vessel without the internal support of a catheter or dilator.· if more than one drug is to be administered, between the individual drug applications, flush the system with 5 to 10 ml normal saline for injection to prevent drug interactions.· after any infusion, injection or bolus application, the system should be flushed with normal saline for injection or locked with a heparin solution per institutional protocol to prevent thrombotic occlusion of the catheter.Potential complications use of an angiodynamics port system involves potential risks normally associated with the insertion or use of any implanted device or indwelling catheter including but not limited to: air embolism catheter disconnection or migration catheter embolization catheter fragmentation catheter pinch-off clot formation drug extravasation (leakage) erosion of vessel and skin implant rejection infection inflammation thromboembolism thrombophlebitis thrombosis necrosis of scarring of skin over implant area vessel trauma post-operative care the incision site should be monitored for signs of infection, inflammation, hematoma, device rotation or erosion.Routine wound care should be given to these sites.The smart port ct implantable port may be used immediately after verification of catheter placement.Instruct patient to avoid any heavy exertion or strenuous activity during the first few days after surgery.General guidelines · each access of an angiodynamics smart port ct implantable port should be performed using aseptic technique.· follow institutional universal precautions.A review of the angiodynamics complaint system noted no adverse trends for this complaint type and product family.This type of complaint continues to be monitored for trends.Reference (b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SMART PORT CT
Common Device Name
PORT & CATHETER, IMPLANTED, SUBCUTANEOUS, INTRAVASCULAR
Manufacturer (Section D)
ANGIODYNAMICS, INC.
603 queensbury avenue
queensbury NY 12804
Manufacturer (Section G)
ANGIODYNAMICS, INC.
603 queensbury avenue
queensbury
Manufacturer Contact
alexandra invencio
603 queensbury avenue
queensbury, NY 12804
MDR Report Key24573386
Report Number1319211-2026-00070
Device Sequence Number16033688
Product Code LJT
UDI-Device Identifier15051684018098
UDI-Public15051684018098
Combination Product (Y/N)N
Initial Reporter StateMI
Initial Reporter CountryUS
PMA/510(K) Number
K101017
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2025
Device Explanted Year2025
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Other,Company Representative
Initial Reporter Occupation Non-Healthcare Professional
Type of Report Initial,Followup
Report Date (Section B) 04/14/2026
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Model NumberH787CT66LTPDVI1
Device Catalogue NumberCT66LTPD-VI
Device Lot NumberA4524037
Was Device Available for Evaluation? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 02/09/2026
Supplement Date Received by Manufacturer03/16/2026
Initial Report FDA Received Date03/11/2026
Supplement Report FDA Received Date04/14/2026
Was Device Evaluated by Manufacturer? (Y/N) No
Date Device Manufactured01/21/2025
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Reuse
Patient Sequence Number1
Outcome Attributed to Adverse Event Death; Life Threatening; Other; Hospitalization;
Patient SexMale
-
-